Yok Lam Kwong
Overview
Explore the profile of Yok Lam Kwong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang H, Fung C, Hwang Y, Lee H, Lau G, Yip S, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):660-669.
PMID: 38383715
In Hong Kong, newly diagnosed multiple myeloma (NDMM) receives bortezomib-based triplet induction. Upfront autologous stem cell transplant (ASCT) is offered to transplant eligible (TE) patients (NDMM ≤ 65 years of...
2.
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab
Qing M, Zhou T, Perova T, Abraham Y, Sweeney C, Krevvata M, et al.
Ann Hematol
. 2024 Jan;
103(6):1989-2001.
PMID: 38233570
Natural killer/T cell lymphoma (NKTCL) is a highly aggressive, heterogeneous non-Hodgkin lymphoma resulting from malignant proliferation of cytotoxic natural killer (NK) or T cells. Previous studies demonstrated variable expression of...
3.
Lao Z, Tse E, Chuncharunee S, Kwong Y, Wei A, Ko B, et al.
Asia Pac J Clin Oncol
. 2023 Jun;
19(6):655-663.
PMID: 37259880
The burden of leukemia and related diseases is rapidly growing in Asia. Currently, there is a paucity of regional collaborative groups/initiatives that focus exclusively on the management of leukemia in...
4.
Tse E, Kwong Y, Goh Y, Bee P, Ng S, Tan D, et al.
Clin Exp Med
. 2023 Feb;
23(6):2895-2907.
PMID: 36795237
In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data...
5.
Ferhanoglu B, Kim T, Karduss A, Brittain D, Tumyan G, Al-Mansour M, et al.
Leuk Lymphoma
. 2022 Oct;
63(14):3317-3330.
PMID: 36200380
Information on Hodgkin lymphoma (HL) is mostly limited to Europe and North America. This real-world, retrospective study assessed treatment pathways and clinical outcomes in adults with stage IIB-IV classical HL...
6.
Chen Y, Chayakulkeeree M, Chakrabarti A, Gan G, Kwong Y, Liu W, et al.
J Antimicrob Chemother
. 2022 Jul;
77(10):2579-2585.
PMID: 35904002
Management of invasive mould infections (IMIs) is challenging in Asia, as awareness among medical practitioners can be low and resources are limited. Timely diagnosis and appropriate treatment of IMIs can...
7.
Thanarajasingam G, Minasian L, Bhatnagar V, Cavalli F, De Claro R, Dueck A, et al.
Lancet Haematol
. 2022 Apr;
9(5):e374-e384.
PMID: 35483398
Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past two decades. Targeted agents, immune and cellular therapies, and...
8.
Tang H, Fung C, Morgan G, Kumar S, Siu L, Ip H, et al.
Ther Adv Hematol
. 2022 Apr;
13:20406207221082043.
PMID: 35465644
Introduction: Bortezomib has been reported to favourably impact the outcomes of (4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. Methods: To address...
9.
Khaled S, Claes K, Goh Y, Kwong Y, Leung N, Mendrek W, et al.
J Clin Oncol
. 2022 Apr;
40(22):2447-2457.
PMID: 35439028
Purpose: Hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication with significant mortality and no approved therapy. HSCT-TMA results from endothelial injury, which activates the lectin pathway of complement....
10.
Lit B, Guo B, Malherbe J, Kwong Y, Erber W
Cancer Rep (Hoboken)
. 2021 Oct;
5(10):e1573.
PMID: 34617422
Background: Acute myeloid leukaemia (AML) results from the clonal expansion of blast cells of myeloid origin driven by genomic defects. The advances in next-generation sequencing (NGS) have allowed the identification...